Edgewise Therapeutics, Inc.

Listed Company

EWTXCIK 0001710072NasdaqLarge AcceleratedPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-167.79M

Total Assets

$552.60M

Equity

$522.26M

Shares Out

107.27M

Op. Cash Flow

$-143.82M

Business

Edgewise Therapeutics, Inc. is a clinical‑stage biopharmaceutical company focused on the discovery, development and commercialization of precision small‑molecule therapies for severe skeletal and cardiac muscle diseases. Its main product candidates include sevasemten, an oral selective fast skeletal myosin inhibitor for Duchenne and Becker muscular dystrophies, and EDG‑7500, an oral cardiac sarcomere modulator for hypertrophic cardiomyopathy, together with additional preclinical cardiometabolic programs. Key business programs are organized around a muscular dystrophy franchise, a cardiovascular franchise and a discovery/preclinical research platform. Clinical development and trials are conducted primarily in the United States and Europe, the company retains global development and commercialization rights, and it relies on third‑party contract development and manufacturing organizations and clinical trial sites for production and distribution.

Summary from filing dated 2025-03-03

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Research and development	151	127	91	54	32
General and administrative	40	32	23	18	11
Total operating expenses	191	159	114	72	43
Loss from operations	−191	−159	−114	−72	−43
Interest income	24	25	14	4	402,000
Total other income	24	25	14	4	402,000
Net loss	−168	−134	−100	−68	−43
Unrealized gain on available-for-sale securities	257,000	321,000	1	−841,000	−514,000
Total comprehensive loss	−168	−133	−99	−68	−43
Net loss per share, basic (in dollars per share)	−1.63	−1.45	−1.57	—	—
Net loss per share, diluted (in dollars per share)	−1.63	−1.45	−1.57	—	—
Weighted-average shares outstanding, basic (in shares)	103	92	64	54	38
Weighted-average shares outstanding, diluted (in shares)	103	92	64	54	38

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	61	42	86	22	16
Marketable securities, available for sale	469	429	232	330	265
Prepaid expenses and other assets	13	5	9	5	3
Total current assets	543	475	327	357	284
Property and equipment, net	8	10	10	9	912,000
Operating lease right-of-use asset	1	2	2	1	—
Other non-current assets	—	262,000	348,000	251,000	548,000
Total assets	553	487	340	367	285
Accounts payable	6	6	4	6	4
Accrued compensation	12	10	6	4	3
Accrued other expenses	8	7	6	6	4
Operating lease liability, current portion	1	996,000	980,000	608,000	—
Total current liabilities	27	24	17	17	11
Operating lease liability, net of current portion	3	4	4	4	—
Total liabilities	30	28	21	20	11
Commitments and contingencies (see note 5)	—	—	—	—	—
Preferred stock, $.0001 par value per share; 200,000,000 shares authorized and no shares issued or outstanding as of December 31, 2025 and December 31, 2024	—	—	—	—	—
Common stock, $.0001 par value per share; 1,000,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 106,249,579 shares and 94,838,466 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively	10,000	9,000	7,000	6,000	5,000
Additional paid-in capital	1,068	837	563	493	352
Accumulated other comprehensive income	677,000	420,000	99,000	−1	−514,000
Accumulated deficit	−546	−379	−245	−145	−77
Total stockholders' equity	522	459	319	347	274
Total liabilities and stockholders' equity	553	487	340	367	285

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−168	−134	−100	−68	−43
Depreciation	2	2	2	400,000	300,000
Stock-based compensation	35	25	18	11	4
Accretion of discount on marketable securities, net	−8	−13	−10	−543,000	—
Amortization of right-of-use asset	182,000	221,000	181,000	170,000	—
Prepaid expenses and other assets	−8	3	−4	−1	−2
Accounts payable	272,000	2	−92,000	47,000	3
Accrued compensation	2	4	2	1	2
Accrued other expenses and other liabilities	691,000	1	526,000	1	3
Lease liability	−748,000	−220,000	−104,000	3	—
Net cash used in operating activities	−144	−109	−92	−53	−34
Purchases of marketable securities	−527	−477	−256	−292	−288
Sales of marketable securities	67	16	20	—	—
Maturities of marketable securities	427	278	344	—	—
Purchases of property and equipment	−256,000	−1	−6	−6	−668,000
Net cash (used in) provided by investing activities	−33	−185	103	−71	−242
Proceeds from issuance of common stock, net of offering costs	187	239	53	129	—
Exercise of stock options	8	9	117,000	405,000	112,000
Payment of deferred offering costs	—	−262,000	−165,000	−251,000	—
Proceeds from Employee Stock Purchase Plan	923,000	888,000	596,000	320,000	248,000
Net cash provided by financing activities	196	249	53	130	186
Net change in cash and cash equivalents	19	−44	64	6	−89
Right-of-use asset obtained in exchange for new operating lease liability, net of tenant improvement receivable	—	—	1	1	—
Property and equipment purchases included in accounts payable and accrued other expenses	199,000	44,000	227,000	3	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro